Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:59:48 EDT Tue 01 Jul 2025
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q16.10.71·0.79240.10.7499-0.0132-1.7776.35011,1460.75  0.763  0.72026.89  0.635819:57:26Jun 2415 min RT 2¢

Recent Trades - Last 10 of 1146
Time ETExPriceChangeVolume
19:57:26Q0.7399-0.023280
19:57:10Q0.7211-0.042270
19:56:34Q0.721-0.042110
19:55:32Q0.7211-0.042443
19:55:02Q0.74-0.0231100
19:53:41Q0.7491-0.0144
19:52:47Q0.7111-0.05299
19:51:55Q0.7199-0.04321
19:51:45Q0.72-0.04311,500
19:51:44Q0.7199-0.043220

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results
2025-01-13 07:00U:IBIONews ReleaseiBio Announces New Investments from Board Members and Officers
2025-01-07 07:00U:IBIONews ReleaseiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
2025-01-02 07:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
2024-11-25 08:00U:IBIONews ReleaseiBio Strengthens Board with Appointment of Two New Independent Directors
2024-11-12 16:05U:IBIONews ReleaseiBio Reports Fiscal First Quarter 2025 Financial Results
2024-10-10 08:00U:IBIONews ReleaseiBio and AstralBio Provide Update on Myostatin Program for Obesity
2024-09-20 16:05U:IBIONews ReleaseiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-09-03 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2024-08-12 16:30U:IBIONews ReleaseiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development